News & Events
26 April 2012 Completion of Placing
16 April 2012 PAGE Meeting 2012
29 March 2012 Physiomics to present new developments of the Virtual Tumour platform at Annual Meeting for American Association for Cancer Research (“AACR”)
22 March 2012 Workshop Invitation – Half-day Workshop on 5th June 2012 at Palazzo del Casinò (Venice)
7 March 2012 Interim Results Statement for the six month period ended 31 December 2011
1 March 2012 New Agreement to advance oncology candidate with global pharma company
31 January 2012 Physiomics to enter new therapeutic area with appointment of SAB member
Virtual Tumour Platform
Physiomics' Virtual Tumour platform predicts optimal drug dosing, scheduling and combinations.
Physiomics helps pharmaceutical and biotechnology companies to determine optimal doses, schedules and combinations for their pre-clinical oncology candidates.
Virtual Tumour provides the following key benefits:
Improve success rates for oncology candidates entering clinical studies, by increasing efficacy- Reduce the time taken to do proof-of-principle
studies - Reduce the cost of xenograft study programmes
(fewer experiments needed) - Provide regulatory agencies with a rationale for the design of a clinical study programme
